Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Gamma-aminobutyric acid type A (GABA_A) receptor α3βxγ2 is a subtype of the pentameric ligand-gated ion channel responsible for mediating fast inhibitory neurotransmission in the mammalian central nervous system (UniProt P34903). It is typically composed of two α3 subunits, two β subunits (β2 or β3), and one γ2 subunit, which together form a chloride-selective pore (PMID: 11689411). This receptor subtype is predominantly expressed in the thalamus, amygdala, and the dorsal horn of the spinal cord, where it plays a crucial role in modulating sensory input and emotional responses (PMID: 21606318). Dysregulation of α3-containing GABA_A receptors is implicated in the pathophysiology of chronic neuropathic pain, generalized anxiety disorders, and certain types of epilepsy (PMID: 15620363). Therapeutic targeting of this receptor involves positive allosteric modulators (PAMs) that bind to the benzodiazepine site at the α3/γ2 interface, enhancing the inhibitory effect of GABA (PubChem CID 3016). Unlike α1-containing receptors which mediate sedation, α3-containing receptors are primarily associated with anxiolytic and analgesic effects (PMID: 19012749). Consequently, drug discovery efforts are focused on developing α3-selective or α2/α3-preferring modulators to treat pain and anxiety while minimizing sedative side effects (PMID: 29351434). These receptors also interact with various endogenous neurosteroids and barbiturates, which further modulate their channel kinetics and inhibitory tone (StatPearls NBK526124).
Positive allosteric modulation of the GABA_A receptor at the benzodiazepine binding site located at the α3/γ2 subunit interface, which increases the frequency of chloride channel opening in response to GABA binding, leading to neuronal hyperpolarization (PMID: 15620363, StatPearls NBK526124).
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Gamma-aminobutyric acid type A receptor alpha 3 subunit-containing complex (GABA_A receptor α3βxγ2) (GABA_A receptor α3βxγ2).